Taiyen Biotech Co Ltd (1737) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Taiyen Biotech Co Ltd (1737) has a cash flow conversion efficiency ratio of 0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$173.44 Million ≈ $5.46 Million USD) by net assets (NT$6.91 Billion ≈ $217.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 1737 equity to assets ratio to measure how much of total assets are equity-financed.
Taiyen Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Taiyen Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 1737 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Taiyen Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taiyen Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
-0.003x |
|
Nova Lifestyle I
NASDAQ:NVFY
|
-0.140x |
|
Simplex Infrastructures Limited
NSE:SIMPLEXINF
|
0.222x |
|
Kwong Lung Enterprise Co Ltd
TWO:8916
|
0.073x |
|
Mkango Resources Ltd
V:MKA
|
3.481x |
|
Arwana Citramulia Tbk
JK:ARNA
|
0.104x |
|
Insecticides (India) Limited
NSE:INSECTICID
|
-0.101x |
|
Nextgreen Global Bhd
KLSE:7241
|
0.093x |
Annual Cash Flow Conversion Efficiency for Taiyen Biotech Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Taiyen Biotech Co Ltd from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Taiyen Biotech Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$6.81 Billion ≈ $214.67 Million |
NT$473.77 Million ≈ $14.93 Million |
0.070x | -29.77% |
| 2024-12-31 | NT$6.67 Billion ≈ $210.07 Million |
NT$660.12 Million ≈ $20.80 Million |
0.099x | +42.64% |
| 2023-12-31 | NT$6.55 Billion ≈ $206.32 Million |
NT$454.54 Million ≈ $14.32 Million |
0.069x | -20.37% |
| 2022-12-31 | NT$6.66 Billion ≈ $209.89 Million |
NT$580.69 Million ≈ $18.29 Million |
0.087x | -5.39% |
| 2021-12-31 | NT$6.51 Billion ≈ $205.21 Million |
NT$600.08 Million ≈ $18.91 Million |
0.092x | +72.78% |
| 2020-12-31 | NT$6.36 Billion ≈ $200.51 Million |
NT$339.36 Million ≈ $10.69 Million |
0.053x | -0.82% |
| 2019-12-31 | NT$6.15 Billion ≈ $193.85 Million |
NT$330.81 Million ≈ $10.42 Million |
0.054x | -26.43% |
| 2018-12-31 | NT$6.16 Billion ≈ $193.93 Million |
NT$449.83 Million ≈ $14.17 Million |
0.073x | -27.65% |
| 2017-12-31 | NT$6.02 Billion ≈ $189.62 Million |
NT$607.87 Million ≈ $19.15 Million |
0.101x | +6.43% |
| 2016-12-31 | NT$5.99 Billion ≈ $188.60 Million |
NT$568.06 Million ≈ $17.90 Million |
0.095x | +44.86% |
| 2015-12-31 | NT$5.86 Billion ≈ $184.65 Million |
NT$383.93 Million ≈ $12.10 Million |
0.066x | +2.83% |
| 2014-12-31 | NT$5.82 Billion ≈ $183.52 Million |
NT$371.06 Million ≈ $11.69 Million |
0.064x | +79.77% |
| 2013-12-31 | NT$5.73 Billion ≈ $180.67 Million |
NT$203.21 Million ≈ $6.40 Million |
0.035x | +49.72% |
| 2012-12-31 | NT$6.53 Billion ≈ $205.60 Million |
NT$154.46 Million ≈ $4.87 Million |
0.024x | -36.43% |
| 2011-12-31 | NT$6.61 Billion ≈ $208.23 Million |
NT$246.09 Million ≈ $7.75 Million |
0.037x | -18.56% |
| 2010-12-31 | NT$6.58 Billion ≈ $207.34 Million |
NT$300.89 Million ≈ $9.48 Million |
0.046x | -16.13% |
| 2009-12-31 | NT$6.57 Billion ≈ $206.92 Million |
NT$358.02 Million ≈ $11.28 Million |
0.055x | -16.99% |
| 2008-12-31 | NT$6.36 Billion ≈ $200.31 Million |
NT$417.51 Million ≈ $13.15 Million |
0.066x | +35.05% |
| 2007-12-31 | NT$6.63 Billion ≈ $208.94 Million |
NT$322.49 Million ≈ $10.16 Million |
0.049x | -26.86% |
| 2006-12-31 | NT$6.96 Billion ≈ $219.34 Million |
NT$462.88 Million ≈ $14.58 Million |
0.066x | -20.34% |
| 2005-12-31 | NT$6.90 Billion ≈ $217.39 Million |
NT$575.91 Million ≈ $18.14 Million |
0.083x | -76.90% |
| 2004-12-31 | NT$7.85 Billion ≈ $247.21 Million |
NT$2.84 Billion ≈ $89.32 Million |
0.361x | -22.55% |
| 2003-12-31 | NT$7.33 Billion ≈ $230.91 Million |
NT$3.42 Billion ≈ $107.73 Million |
0.467x | -- |
About Taiyen Biotech Co Ltd
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers beauty and skincare, and cleaning products; salt products; and leisure and pet foods, as well as health supplement. The company was founded in 1952 and is based in Tainan City, Taiwan.